Journals

Year, pages: 2023, 287 - 293

The 5-year overall survival rate of acute myeloid leukemia (AML) is less than 30%. Improving clinical outcomes is still a clinical challenge for AML treatment. Simultaneous use of chemotherapeutic drugs and targeting of apoptosis pathways has become a first-line clinical treatment for AML. Myeloid cell leukemia 1 (MCL-1) is a candidate target for AML treatment. In this study, we demonstrated that inhibition of the anti-apoptotic protein MCL-1 by AZD5991 synergistically increased chemotherapeutic agent cytarabine (Ara-C)-induced apoptosis in AML cell lines and primary patient samples. Apoptosis induced by a combination of Ara-C and AZD5991 was partially dependent on caspase activity and Bak/Bax. The downregulation of MCL-1 by Ara-C and the enhancement of Ara-C-induced DNA damage through inhibition of MCL-1 are potential mechanisms underlying the synergistic anti-AML activity between Ara-C and AZD5991. Our data support the application of MCL-1 inhibitor in combination with the conventional chemotherapeutic agent for the clinical treatment of AML.

ISO 690:

Wang, Y.: , Wang, Y.: Wang, D.: , Wang, Y.: Wang, D.: Wang, Y.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: Wang, G.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: Wang, G.: Wu, S.: 2023. Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia. In NEOPLASMA, vol. 70, no.2, pp. 287-293. 0028-2685. DOI: https://doi.org/10.4149/neo_2023_221217N1185

APA:

Wang, Y.: , Wang, Y.: Wang, D.: , Wang, Y.: Wang, D.: Wang, Y.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: Wang, G.: , Wang, Y.: Wang, D.: Wang, Y.: Yang, H.: Wang, G.: Wu, S.: (2023). Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia. NEOPLASMA, 70(2), 287-293. 0028-2685. DOI: https://doi.org/10.4149/neo_2023_221217N1185

Publisher: AEPress, Ltd.